View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Novo Nordisk A/S: Annual update

Our credit view of this issuer reflects A degree of M&A risk.

Novo Nordisk A/S: Annual update

Our credit view of this issuer reflects A degree of M&A risk.

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

GSK: 14 directors

Fourteen Directors at GSK sold/sold after exercising options 161,136 shares at between 2,191p and 2,212p. The significance rating of the trade was 88/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's d...

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
Martial Descoutures
  • Martial Descoutures
Martial Descoutures
  • Martial Descoutures

Novo Nordisk A/S: Annual update

Our credit view of this issuer reflects A degree of M&A risk.

Novo Nordisk A/S: Sales and EBITDA correction will widen in 2026, a cr...

Weaker 2026 outlook will pressure cash flow and slightly increase leverage

AstraZeneca PLC: Collaboration with CSPC strengthens weight-management...

AstraZeneca will pay $1.2 billion upfront, with up to $3.5 billion in milestones. The deal broadens its position in the obesity-care market with little immediate effect on its credit quality

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch